Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients

被引：48

作者：

Brune A. ^{[1
]}

Metze D. ^{[1
]}

Luger T.A. ^{[1
]}

Ständer S. ^{[1
,2
]}

机构：

[1] Klin. Poliklin. F. Hautkrankheiten, Univ. Klin. Münster

[2] Klin. Poliklin. F. Hautkrankheiten, Univ. Klin. Münster, 48149 Münster

来源：

Der Hautarzt | 2004年 / 55卷 / 12期

关键词：

Atopic dermatitis; Itch; Naltrexone; Prurigo;

D O I：

10.1007/s00105-004-0802-8

中图分类号：

学科分类号：

摘要：

Background and Objectives.The perception of pruritus is modified by endogenous and exogenous opioids via central opiate receptors and can be suppressed with opioid receptor antagonists. The aim of this investigation was to describe the efficacy and safety of naltrexone, an orally active opiate antagonist, in the treatment of severe, otherwise intractable pruritus of varying origins. Patients. A total of 133 patients with pruritus caused by inflammatory skin diseases (asteatotic dermatitis, atopic dermatitis, prurigo, and psoriasis vulgaris), liver- and renal diseases, cutaneous lymphoma, as well as with pruritus of unknown origin were treated with naltrexone (Nemexin™) 50 to 150 mg daily. Results. A therapeutic response was achieved in 86 of the 133 (64.6%) patients. Naltrexone was most effective in prurigo nodularis, cutaneous lymphoma and pruritus of unknown origin. Tachyphylaxis occurred in 13% of the patients, but appeared late, and could be counterbalanced by raising the dosage. Adverse drug effects were restricted to the first two weeks of treatment and included mainly neurological (dizziness, headache, fatigue) and gastrointestinal (nausea, vomiting, diarrhea) symptoms. Conclusions. The oral opiate antagonists may well be an effective, well-tolerated therapy for intractable pruritus in many diseases.

引用

页码：1130 / 1136

页数：6

共 25 条

[1]

Andersen L.W., Friedberg M., Lokkegaard N., Naloxone in the treatment of uremic pruritus: A case history, Clin Nephrol, 21, pp. 355-356, (1984)

[2]

Banerji D., Fox R., Seleznick M., Lockey R., Controlled antipruritic trial of nalmefene in chronic urticaria and atopic dermatitis, J Allergy Clin Immunol, 81, (1988)

[3]

Bergasa N.V., Alling D.W., Talbot T.L., Et al., Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial, Ann Intern Med, 123, pp. 161-167, (1995)

[4]

Bergasa N.V., Schmitt J.M., Talbot T.L., Et al., Open-label trial of oral nalmefene therapy for the pruritus of cholestasis, Hepatology, 27, pp. 679-684, (1998)

[5]

Bergasa N.V., Alling D.W., Talbot T.L., Et al., Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study, J Am Acad Dermatol, 41, pp. 431-434, (1999)

[6]

Bernstein J.E., Swift R., Relief of intractable pruritus with naloxone, Arch Dermatol, 115, pp. 1366-1367, (1979)

[7]

Bernstein J.E., Swift R.M., Soltani K., Lorincz A.L., Antipruritic effect of an opiate antagonist, naloxone hydrochloride, J Invest Dermatol, 78, pp. 82-83, (1982)

[8]

Ghura H.S., Patterson A.D., Carmichael A.J., Naltrexone in the treatment of renal itch, Br J Dermatol, 139, 51 SUPPL., (1998)

[9]

Gonzalez J.P., Brogden R.N., Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence, Drugs, 35, pp. 192-213, (1988)

[10]

Heyer G., Dotzer M., Diepgen T.L., Handwerker H.O., Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis, Pain, 73, pp. 239-243, (1997)

← 1 2 3 →